AngioDynamics, Inc. (ANGO) Stock Forecast
ANGO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $19.75 average of analyst targets
- Upside to target
- +75.7% from the latest close
- Next earnings
- —
- 52-week range
- $9.70 – $16.13
ANGO analyst ratings
4 analystsNumber of analysts at each rating.
ANGO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ANGO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Nov '26) | −$0.07 | −$0.11 | −$0.02 | $0.00 | 0.0% | 3 |
| Next quarter (Feb '27) | −$0.09 | −$0.10 | −$0.07 | $0.02 | −550.0% | 3 |
| Current fiscal year (FY2027) | −$0.28 | −$0.29 | −$0.27 | −$0.15 | −86.7% | 3 |
| Next fiscal year (FY2028) | −$0.11 | −$0.15 | −$0.06 | −$0.28 | +59.5% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ANGO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Nov '26) | $84.3M | $83.0M | $85.4M | +6.1% | 4 |
| Next quarter (Feb '27) | $83.2M | $81.9M | $84.0M | +6.2% | 4 |
| Current fiscal year (FY2027) | $337.7M | $337.0M | $338.4M | +5.5% | 4 |
| Next fiscal year (FY2028) | $354.9M | $352.0M | $360.1M | +5.1% | 4 |
ANGO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ANGO revenue: reported and forecast
ANGO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Nov '26) | −$0.06 | −$0.08 | −$0.08 | −$0.08 | −$0.07 | +22.2% | 1 up · 1 down |
| Next quarter (Feb '27) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.09 | +50.0% | 1 up · 0 down |
| Current fiscal year (FY2027) | −$0.27 | −$0.27 | −$0.27 | −$0.27 | −$0.28 | +5.7% | 1 up · 0 down |
| Next fiscal year (FY2028) | −$0.04 | −$0.04 | −$0.04 | −$0.04 | −$0.11 | +151.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ANGO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ANGO beat in 10 of 12.
What analysts expect from ANGO
4 analysts cover AngioDynamics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $19.75, 75.7% above the latest close of $11.24. Analysts expect earnings of −$0.28 per share for FY2027, −86.7% from a year earlier. For FY2028 the average estimate is −$0.11 per share on revenue of $354.9 million. AngioDynamics beat the EPS estimate in 10 of the last 12 quarters.
Related: ANGO income statement, ANGO key metrics, ANGO chart. See the ANGO stock overview for the latest quote and news.
ANGO forecast FAQ
What is AngioDynamics's price target?
The average analyst price target for AngioDynamics is $19.75, 75.7% above the latest close of $11.24.
Is AngioDynamics a buy, hold or sell?
Of 4 analysts covering AngioDynamics, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AngioDynamics's EPS forecast?
Analysts forecast −$0.28 per share for FY2027 (range −$0.29 to −$0.27); for FY2028 the estimate is −$0.11.
What is AngioDynamics's revenue forecast?
The average revenue estimate for FY2027 is $337.7 million, growth of 5.5%; for FY2028 it is $354.9 million.
Does AngioDynamics usually beat earnings estimates?
AngioDynamics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.